BIO Applauds House Passage of Food and Drug Administration Reauthorization Act (FDARA)

Urges swift Senate vote to ensure continuity of critical FDA functions   Washington, DC (July 12, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the Food and Drug Administration Reauthorization Act (FDARA) by the U.S. House of Representatives:

BIO Statement on EPA’s Proposed 2018 Renewable Fuel Standards

Washington, D.C. (July 5, 2017) – The Environmental Protection Agency’s proposed Renewable Fuel Standards for 2018 and biomass-based diesel volume for 2019 must be improved to support investment and capacity building for advanced and cellulosic biofuels, the Biotechnology Innovation Organization (BIO) said today. 

BIO Applauds Bipartisan Introduction of Renewable Chemicals Tax Credit

BIO and its members thank Rep. Bill Pascrell (D-NJ) and Reps. Ryan Costello (R-PA), Brian Fitzpatrick (R-PA) and Linda Sánchez (D-CA) for introducing the Renewable Chemicals Act of 2017.

The BIO International Convention Closes after Four “Breakthrough” Days in San Diego

The 2017 BIO International Convention  (BIO 2017), hosted by the Biotechnology Innovation Organizatio (BIO), closed today after four days of immersive, compelling programming united under the theme of “Breakthrough.”  BIO 2017 recognized past, present and future biotech breakthroughs that heal, feed and fuel the world

BIO Expands Cooperation with China-Based Pharma Group

Memorandum of Understanding for Cooperation continues the longstanding relationship between BIO and RDPAC and deepens our cooperative efforts.

BIO Statement of Support for the Introduction of the STRONGER Patents Act of 2017

Bill cracks down on false or deceptive patent demand letters, ensures urgently-needed fairness and finality in Patent Office post grant proceedings, eliminates diversion of PTO user fees, and helps American research-intensive companies protect their investments in innovation

New Report: Licensing of Academic Patents Has Contributed Up to $1.3 Trillion to US Economy

Tech Transfer Has Supported Up to 4.2 Million Jobs Since 1996

BIO Releases Bioscience Economic Development Guide

At the 2017 BIO International Convention, cabinet-level appointees representing Texas, Massachusetts, Rhode Island, and Puerto Rico participated in the report's release by discussing bioscience industry economic development and state policies that have proven successful in assisting industry growth.

BIO comments to FDA Regarding the Regulation of Intentionally Altered Genomic DNA in Animals

BIO appreciates this opportunity to provide comments to the Food and Drug Administration (FDA) on its request for comments on the draft guidance for industry (GFI) #187, entitled Regulation of Intentionally Altered Genomic DNA in Animals2. This draft guidance would revise GFI #187 entitled “Regulation of Genetically Engineered Animals Containing Heritable Recombinant DNA Constructs” (current GFI #187)3. 

America Must Strengthen Bioscience Innovation Leadership

Regulatory Systems Must Be Consistent across Agencies and Based on Actual Risk   Washington, D.C. (June 20, 2017) – In comments submitted to the U.S. Depart of Agriculture (USDA) and U.S. Food and Drug Administration (FDA), the Biotechnology Innovation Organization (BIO) urges the Administration to take consistent and decisive steps to unleash the full potential of American bio-based innovation in food, feed, agriculture, and animal health. Doing so will reinforce the United States’ global leadership in these sectors and foster the creation of more well-paying jobs at innovative companies throughout the country.